When a Drug Study Abruptly Ends, Volunteers Are Left to Cope
On March 21, 2019, the staff at the Penn Memory Center in Philadelphia was scrambling to learn more about an early-morning announcement: Two pharmaceutical companies, Biogen and Eisai, would discontinue their clinical trial of a drug intended to slow the progression of early Alzheimer’s disease. A “futility analysis” had shown that aducanumab, being studied in…